This trial is evaluating whether SPECTRUM NRC 102/103 investigational cigarettes will improve 7 primary outcomes and 3 secondary outcomes in patients with Chronic Pain. Measurement will happen over the course of Baseline, weekly for 5 weeks.
This trial requires 60 total participants across 2 different treatment groups
This trial involves 2 different treatments. SPECTRUM NRC 102/103 Investigational Cigarettes is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.
"For patients presenting with chronic pain, there is no one single sign to rule in or out chronic pain. Rather, a combination of clinical signs is necessary to support the existence that the patient has chronic pain." - Anonymous Online Contributor
"Different types of pain are likely to have different causes, including genetics, CNS dysfunction, neuroactive chemicals or the immune system, but there is no consistent evidence to confirm any explanation." - Anonymous Online Contributor
"Chronic pain is very common. About 30 million American adults have chronic pain, accounting for half of visits to the doctor and up to a third of disability." - Anonymous Online Contributor
"There is considerable evidence that [chronic pain](https://www.withpower.com/clinical-trials/chronic-pain) remains largely a disease of unknown cause, for which no cure can currently be demonstrated. The pain is the main motive for seeking healthcare and it persists for a number of reasons." - Anonymous Online Contributor
"The treatment of chronic pain is highly varied. A greater focus on prevention and treating chronic pain should be the goal of care for the affected individual." - Anonymous Online Contributor
"Chronic pain affects around 10% of the adult population, most commonly affecting the back, neck, and shoulders. Pain is mostly experienced in people aged between 55 and 65." - Anonymous Online Contributor
"The C-SCID regimen for nicotine inhalation is effective and well tolerated by patients with a wide variety of chronic non-malignant diseases. Results from a recent paper highlight the utility of this approach in smokers who do not respond to alternative approaches." - Anonymous Online Contributor
"Chronic pain is very serious in terms of the long-term prognosis or the functional impact. In the case of chronic pain, only timely and comprehensive management can preserve the quality of life of patients, minimize their disability and, finally, the cost of healthcare care and of institutionalization." - Anonymous Online Contributor
"NRC 102 and NRC 103 products were not associated with excessive smoking-like side effects compared with the corresponding commercialized products, such as aldehydes, acetone, ethyl acetate, ketones and a variety of phthalates and toluenes, in addition to naphthalene. This profile is consistent with the high toxicity of the constituent chemicals." - Anonymous Online Contributor
"RCTs have demonstrated the safety and efficacy of SNCI. The current findings suggest that SNCI may be at increased risk of adverse events when used by a population with a higher age and greater likelihood of smoking, and a lower willingness to quit cigarettes compared with individuals at lower risk for long-term smoking cessation." - Anonymous Online Contributor
"The use of NDC 102 / NDC 103 investigational cigarettes appears to be no different from commercially available NDCs in regard to potency and nicotine content, and therefore does not appear a credible health claim. However, there is no doubt that NDC 102 / NDC 103 offer clinicians and researchers a much greater choice in terms of cigarette formats and nicotine contents, which is also a significant research and educational advantage. The use of NDC 102 / NDC 103 investigational cigarettes should widen the scope of NDC evaluation and research." - Anonymous Online Contributor
"In a recent study, findings of this study suggest that NDs with a low RYO tobacco content could be effective and acceptable in treating patients with various forms of CP (NHP), while patients with moderate or severe pain may benefit the most from NDs containing a high RYO tobacco content." - Anonymous Online Contributor